Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects.

Aging cell | 2020

To see if variations in timing of rapamycin (Rapa), administered to middle aged mice starting at 20 months, would lead to different survival outcomes, we compared three dosing regimens. Initiation of Rapa at 42 ppm increased survival significantly in both male and female mice. Exposure to Rapa for a 3-month period led to significant longevity benefit in males only. Protocols in which each month of Rapa treatment was followed by a month without Rapa exposure were also effective in both sexes, though this approach was less effective than continuous exposure in female mice. Interpretation of these results is made more complicated by unanticipated variation in patterns of weight gain, prior to the initiation of the Rapa treatment, presumably due to the use of drug-free food from two different suppliers. The experimental design included tests of four other drugs, minocycline, β-guanidinopropionic acid, MitoQ, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), but none of these led to a change in survival in either sex.

Pubmed ID: 33145977 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIA NIH HHS, United States
    Id: T32 AG021890
  • Agency: NIA NIH HHS, United States
    Id: U01 AG022307
  • Agency: NCI NIH HHS, United States
    Id: P30 CA034196
  • Agency: NIA NIH HHS, United States
    Id: U01 AG022303
  • Agency: NIA NIH HHS, United States
    Id: P30 AG013319
  • Agency: NIA NIH HHS, United States
    Id: P30 AG024824
  • Agency: NIA NIH HHS, United States
    Id: U24 AG066346
  • Agency: NIA NIH HHS, United States
    Id: U01 AG022308
  • Agency: Medical Research Council, United Kingdom
    Id: MC_UU_00015/3

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


DBA/2J (tool)

RRID:IMSR_JAX:000671

Mus musculus with name DBA/2J from IMSR.

View all literature mentions

BALB/cByJ (tool)

RRID:IMSR_JAX:001026

Mus musculus with name BALB/cByJ from IMSR.

View all literature mentions

C3H/HeJ (tool)

RRID:IMSR_JAX:000659

Mus musculus with name C3H/HeJ from IMSR.

View all literature mentions

C3D2F1/J (tool)

RRID:IMSR_JAX:100004

Mus musculus with name C3D2F1/J from IMSR.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

CByB6F1/J (tool)

RRID:IMSR_JAX:100009

Mus musculus with name CByB6F1/J from IMSR.

View all literature mentions